興齊眼藥(300573.SZ):撤回溶菌酶滴眼液的註冊申請
格隆匯8月2日丨興齊眼藥(300573.SZ)公佈,收到國家藥品監督管理局核准簽發的《藥品註冊申請終止通知書》,同意公司撤回溶菌酶滴眼液的註冊申請。溶菌酶滴眼液適應症為:適用於慢性結膜炎。本次註冊申請是在公司已上市溶菌酶滴眼液(國藥準字H20190023)基礎上進行的補充申請:增加規格等變更,公司於2023年10月向國家藥監局遞交該補充申請並獲受理。經審慎研究,結合研發策略,公司決定主動撤回本次補充申請。該藥品註冊申請的主動撤回並終止對已上市產品及公司研發工作無重大影響,也不會對公司當期及未來生產經營與業績產生重大影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.